Pharmapedia Pro
Back to News
Regulation18 Nov 2026Source: FDA

FDA Launches Global Reliance Disclosure Program to Share Regulatory Reviews

The US Food and Drug Administration has announced the launch of the Global Reliance Disclosure Program. This initiative allows the FDA to share minimally redacted approval packages and detailed scientific assessments with companies, who can then submit them to regulatory authorities outside the United States. The program aims to help international health authorities rely on FDA scientific reviews to accelerate patient access to innovative therapies.

The program launched with a President's Emergency Plan for AIDS Relief tentative approval for lenacapavir, a drug for HIV prevention and treatment. The FDA plans to expand the program in January 2027 to include all novel drugs and biologics, as well as introduce a pathway for already approved and licensed products. Applicants must request participation within ten calendar days of approval to receive the package for submission to a foreign regulatory authority.

Key points

  • The Global Reliance Disclosure Program shares minimally redacted FDA approval packages with companies for foreign regulatory use.
  • The initiative aims to reduce duplicate reviews by international health authorities and speed up global patient access.
  • It launched with a PEPFAR tentative approval for lenacapavir and will expand to all novel drugs and biologics.
  • Applicants must request participation within 10 calendar days of approval and confirm submission to a foreign authority.

What it means for you

This FDA initiative provides a mechanism for regulatory authorities worldwide to leverage detailed US scientific assessments in order to accelerate local product approvals. Clinicians and pharmacists in Pakistan should check with the Drug Regulatory Authority of Pakistan regarding local registration status and guidance for any therapies affected by international regulatory reliance updates.

Read the original announcement

FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide

Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.